What is EnteroBiotix?
EnteroBiotix is a pioneering biopharmaceutical entity dedicated to the development of advanced microbiome-based therapies. The company is currently focused on the clinical advancement of its lead candidate, EBX-102-02, which is being evaluated as a potential first-in-class disease-modifying therapy for irritable bowel syndrome. Following promising results from the TrIuMPH Phase 2a trial, the organization is now advancing into the Phase 2b RISE trial. This strategic focus on high-impact, full-spectrum microbiome solutions places EnteroBiotix at the forefront of therapeutic innovation, addressing significant unmet needs in chronic digestive health conditions through rigorous scientific methodology and clinical validation.
How much funding has EnteroBiotix raised?
EnteroBiotix has raised a total of $91.6M across 7 funding rounds:
Angel/Seed
$4M
Series A
$21.5M
Debt
$14.6M
Private Equity
$19.8M
Private Equity
$1.4M
Private Equity
$5.3M
Unspecified
$25M
Angel/Seed (2019): $4M with participation from NCIMB, Bank Workers Charity, Equity Gap, University of Aberdeen, Fund Twenty8, SIS Ventures, Scottish Enterprise, Gabriel, Syndicate Room, and Barwell
Series A (2021): $21.5M led by Thairm Bio, Kineticos Ventures, SIS Ventures, and Scottish Enterprise
Debt (2024): $14.6M supported by Scottish National Investment Bank
Private Equity (2024): $19.8M featuring Kineticos
Private Equity (2025): $1.4M, investors not publicly disclosed
Private Equity (2026): $5.3M, investors not publicly disclosed
Unspecified (2026): $25M led by Scottish National Investment Bank
Key Investors in EnteroBiotix
Scottish National Investment Bank
The Scottish National Investment Bank is a development investment bank established to provide long-term, patient capital investments for businesses, projects, and communities across Scotland.
Kineticos
Kineticos is a specialized management consulting firm serving the life science industry, focused on corporate strategy, operational execution, and innovation services.
Scottish Enterprise
Scottish Enterprise is a national economic development agency and a non-departmental public body of the Scottish Government, supporting high-growth businesses.
What's next for EnteroBiotix?
With the recent influx of capital, EnteroBiotix is poised to execute its next phase of operational scaling and clinical development. The primary objective remains the successful completion of the RISE trial, which serves as a critical milestone for the company's long-term commercialization strategy. By maintaining a robust balance sheet, the firm can effectively navigate the complexities of late-stage clinical trials while exploring potential partnerships to expand its therapeutic platform. The strategic deployment of these funds will likely prioritize the acceleration of its R&D infrastructure and the strengthening of its intellectual property portfolio, ensuring that EnteroBiotix remains a leader in the evolving field of microbiome-based medicine.
See full EnteroBiotix company page
